IHE vs IXJ: 0.39% vs 0.41% Fees — Which Healthcare ETF Wins?

In an era where every basis point counts, the IHE versus IXJ debate pits pure U.S. pharma concentration against broad global healthcare diversification. With expense ratios separated by just 0.02 percentage points, the decision often boils down to currency risk, sector concentration, and how much an investor believes in the American drug pipeline versus a multi-industry global approach.

The healthcare ETF landscape presents investors with a classic conundrum: targeted U.S. pharmaceutical exposure versus diversified global healthcare. The iShares U.S. Pharmaceuticals ETF (IHE) and iShares Global Healthcare ETF (IXJ) sit at the center of this debate, with more than $5.5 billion in combined assets under management. While both funds fall under the healthcare umbrella, their underlying portfolios and investment philosophies diverge sharply, creating distinct risk-return profiles that demand careful consideration.

“

For a $100,000 investment, that's a $20 annual difference pre-cost, but compounded over 30 years at a 7% return, it balloons to over $1,800 in savings for IHE.

At the heart of the comparison is a fundamental geographic and industry-based split. IHE limits itself to U.S.-domiciled pharmaceutical companies—drug manufacturers, distributors, and related service providers. This focus has historically offered pure-play exposure to America's drug innovation pipeline and demographic tailwinds, but also leaves investors vulnerable to U.S.-specific regulatory and political risks, such as drug pricing reforms. IXJ, by contrast, casts a far wider net, encompassing not just U.S. pharma giants but also international healthcare stalwarts, medical device makers, biotech innovators, and healthcare service providers from Europe, Asia, and beyond. With 110 holdings spread globally, IXJ dampens single-country risk and captures broader secular growth in global healthcare spending.

The numbers underscore the concentration difference. IHE's top two holdings—Johnson & Johnson and Eli Lilly—account for a staggering 43.25% of the fund, with 56 total holdings. IXJ's top two, Eli Lilly and Johnson & Johnson, represent a more modest 17.50%, and no single position dominates. This means that IHE's performance is essentially a leveraged bet on a handful of U.S. pharma leaders; any stumble by JNJ or LLY would disproportionately impact returns. IXJ, with its 110 holdings, offers a smoother ride albeit with potentially lower upside during U.S. pharma booms.

On the cost front, the differences are almost negligible but not to be ignored. IHE charges 0.39% annually, while IXJ levies 0.41%—a 0.02 percentage point gap. For a $100,000 investment, that's a $20 annual difference pre-cost, but compounded over 30 years at a 7% return, it balloons to over $1,800 in savings for IHE. Yield hunters find little divergence either: both ETFs distribute roughly 1.50% in trailing dividends, with IXJ at 1.44% and IHE estimated near the same level. Income-oriented investors will thus focus on portfolio stability and growth potential rather than yield differentiation.

Liquidity and scale tilt toward IXJ, with $4.1 billion in AUM compared to IHE's $1.4 billion. Higher AUM generally translates to tighter bid-ask spreads, greater institutional participation, and lower transaction costs—factors that active traders and large institutions prioritize. Yet IHE's niche appeal often attracts tactical allocators who want to overweight U.S. pharma during favorable policy windows or innovation cycles.